Published in Nat Med on April 01, 1996
Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs (1999) 4.32
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol (1999) 3.47
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut (2005) 2.13
Tumour markers of prognosis in colorectal cancer. Br J Cancer (1999) 1.68
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut (1999) 1.63
Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer (2007) 1.61
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer (1998) 1.53
Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia (2007) 1.49
p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Mol Cell Biol (2001) 1.43
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res (2009) 1.39
Matrix metalloproteinases and their inhibitors in gastric cancer. Gut (1998) 1.30
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol (2002) 1.27
Proteolysis in human breast and colorectal cancer. Br J Cancer (1999) 1.27
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther (2008) 1.22
Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res (2004) 1.20
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis (2009) 1.20
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol (2005) 1.14
Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol (2008) 1.08
Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg (2000) 1.08
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer (2012) 1.08
Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol (2005) 1.03
Signaling Transduction Network Mediated by Tumor Suppressor/Susceptibility Genes in NPC. Curr Genomics (2009) 1.03
Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer (2002) 1.00
Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One (2009) 1.00
BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford) (2015) 0.97
The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer (2001) 0.97
Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem (2012) 0.97
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol (2012) 0.96
Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer (2006) 0.94
Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun (2011) 0.94
Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer (1998) 0.93
Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation. J Exp Med (2013) 0.93
Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene (2013) 0.92
IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One (2012) 0.91
Matrix metalloproteinases in gastrointestinal cancer. Gut (1998) 0.91
Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis (2004) 0.91
Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol (2009) 0.91
Surrogate markers in antiangiogenesis clinical trials. Br J Cancer (2003) 0.90
Proteolysis in colorectal cancer. Mol Pathol (1999) 0.89
Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J Biol Chem (2013) 0.89
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer (2012) 0.88
The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer (2007) 0.88
Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. J Biol Chem (2012) 0.88
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs (2007) 0.88
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis. BMC Cancer (2010) 0.88
Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One (2011) 0.88
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol Cancer (2014) 0.87
Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem (2011) 0.86
Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol (2001) 0.86
Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer (2006) 0.86
Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J Virol (2000) 0.85
Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int J Colorectal Dis (2006) 0.85
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer (2010) 0.84
Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas. Oncol Lett (2011) 0.84
Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol (2005) 0.84
Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Metastasis (1999) 0.83
Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion. Adv Exp Med Biol (2015) 0.83
Nano to micro delivery systems: targeting angiogenesis in brain tumors. J Angiogenes Res (2010) 0.82
MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics (2011) 0.80
Role of interstitial collagenase gene promoter polymorphism in the etiology of gastric cancer. Saudi J Gastroenterol (2014) 0.80
Proteases as prognostic markers in cancer. BMJ (1998) 0.80
Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol (2016) 0.79
Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma. Mol Clin Oncol (2015) 0.79
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis (1997) 0.79
Mmp1a and Mmp1b are not functional orthologs to human MMP1 in cigarette smoke induced lung disease. Exp Toxicol Pathol (2014) 0.78
A single step purification for autolytic zinc proteinases. Bioorg Med Chem Lett (2009) 0.78
Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer. Dig Dis Sci (2012) 0.78
Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer. Biomed Rep (2014) 0.77
Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis. Carcinogenesis (2013) 0.77
Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci (2002) 0.77
Optical tecnology developments in biomedicine: history, current and future. Transl Med UniSa (2011) 0.77
Controlled release from recombinant polymers. J Control Release (2014) 0.77
Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer (2003) 0.76
Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase. Trans Am Ophthalmol Soc (2002) 0.76
Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer. Oncotarget (2016) 0.76
Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. Int J Clin Exp Pathol (2015) 0.76
Correlations of polymorphisms in matrix metalloproteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas. Asian J Neurosurg (2016) 0.75
Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol (2015) 0.75
IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System. Front Immunol (2017) 0.75
Differential expression of M3 muscarinic receptors in progressive colon neoplasia and metastasis. Oncotarget (2017) 0.75
Redox-sensitive gene-regulatory events controlling aberrant matrix metalloproteinase-1 expression. Free Radic Biol Med (2014) 0.75
Proteolysis in Helicobacter pylori-Induced Gastric Cancer. Toxins (Basel) (2017) 0.75
Distinct biological events generated by ECM proteolysis by two homologous collagenases. Proc Natl Acad Sci U S A (2016) 0.75
Anacyclus Pyrethrum Extract Exerts Anticancer Activities on the Human Colorectal Cancer Cell Line (HCT) by Targeting Apoptosis, Metastasis and Cell Cycle Arrest. J Gastrointest Cancer (2016) 0.75
Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One (2017) 0.75
Curative in situ ablation of colorectal liver metastases-experimental and clinical implementation. Int J Colorectal Dis (2006) 0.75
Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells. Biochem J (2017) 0.75
[Clinical, pathological and molecular prognostic factors in colorectal carcinomas]. Pathologe (2003) 0.75
Sequence of chicken ovalbumin mRNA. Nature (1978) 6.73
Loss of Gastro-intestinal-specific Antigen in Neoplasia. Br Med J (1962) 2.59
Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol (2004) 2.14
An analysis of the anatomical basis for the mechanical response to motor nerve stimulation of the rat vas deferens. J Physiol (1977) 1.97
Intraventricular neurocytoma. Australas Radiol (1996) 1.93
Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res (1997) 1.84
Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol (2001) 1.67
The complete amino-acid sequence of hen ovalbumin. Eur J Biochem (1981) 1.66
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol (1998) 1.64
Plasmin, fibrin degradation and angiogenesis. Nat Med (1996) 1.59
Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem (1999) 1.33
Matrix metalloproteinases and their inhibitors in gastric cancer. Gut (1998) 1.30
Incorporation of 6-thioguanosine and 4-thiouridine into RNA. Application to isolation of newly synthesised RNA by affinity chromatography. Eur J Biochem (1978) 1.28
Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. J Gen Virol (1984) 1.22
Complete amino acid sequence of the neurone-specific gamma isozyme of enolase (NSE) from human brain and comparison with the non-neuronal alpha form (NNE). Eur J Biochem (1988) 1.21
A molecular approach to the complement system. Curr Top Cell Regul (1978) 1.16
The induction of azaguanine-resistant mutants in cultured Chinese hamster cells by reactive derivatives of carcinogenic hydrocarbons. Mutat Res (1973) 1.14
Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem (1991) 1.12
Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol (1993) 1.10
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Discrimination between Gyrodactylus salaris, G. derjavini and G. truttae (Platyhelminthes: Monogenea) using restriction fragment length polymorphisms and an oligonucleotide probe within the small subunit ribosomal RNA gene. Parasitology (1995) 1.09
Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur J Biochem (1988) 1.08
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol (2001) 1.08
The sentinel pile and Sir Benjamin Collins Brodie. Surg Gynecol Obstet (1966) 1.08
Pelvic inflammatory disease and puerperal sepsis in Ethiopia. I. Etiology. Am J Obstet Gynecol (1980) 1.08
Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut (1993) 1.08
Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol (2001) 1.07
Changes in DNA and RNA synthesis and associated enzyme activities after the stimulation of serum-depleted BHK21-C13 cells by the addition of serum. Exp Cell Res (1974) 1.06
Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett (1995) 1.06
The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol (1988) 1.05
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer (1993) 1.04
Conservation of ribosomal RNA during compensatory renal hypertrophy. A major mechanism in RNA accretion. J Cell Biol (1976) 1.04
Expression of Wnt genes in early wound healing. Wound Repair Regen (1999) 1.04
Primary structure of bovine complement activation fragment C4a, the third anaphylatoxin. Purification and complete amino acid sequence. Biochem J (1982) 1.03
The purification and characterization of bovine C4, the fourth component of complement. Biochem J (1979) 1.02
In situ hybridisation of albumin mRNA in normal liver and hepatocellular carcinoma with a digoxigenin labelled oligonucleotide probe. J Clin Pathol (1992) 1.01
Analysis of the nucleoprotein gene identifies distinct lineages of viral haemorrhagic septicaemia virus within the European marine environment. Virus Res (1999) 0.99
Purification and characterization of subcomponent C1q of the first component of bovine complement. Biochem J (1979) 0.99
Cytochrome P450 expression in oesophageal cancer. Gut (1994) 0.98
Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence. Eur J Biochem (1987) 0.98
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem (1998) 0.98
Thiol and disulphide contents of hen ovalbumin. C-terminal sequence and location of disulphide bond. Biochem J (1970) 0.96
Babies of mothers with leprosy have small placentae, low birth weights and grow slowly. Br J Obstet Gynaecol (1980) 0.96
The amino acid sequence of the small monomeric phosphoglycerate mutase from the fission yeast Schizosaccharomyces pombe. Biochem J (1994) 0.95
Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol (1998) 0.95
Proceedings: Observations on the origin of the complex mechanical response to motor nerve stimulation of the rat vas deferens. J Physiol (1976) 0.95
The serine proteinase chain of human complement component C1s. Cyanogen bromide cleavage and N-terminal sequences of the fragments. Biochem J (1983) 0.94
The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets (2004) 0.94
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol (1995) 0.94
Replacement of asparagine by aspartic acid in hen ovalbumin and a difference in immunochemical reactivity. Biochem J (1972) 0.92
Studies on the maintenance of cytochromes P-450 and b5, monooxygenases and cytochrome reductases in primary cultures of rat hepatocytes. FEBS Lett (1985) 0.92
Evidence for a soluble lymphocyte factor in the transplacental transmission of T-lymphocyte responses to Mycobacterium leprae. Nature (1976) 0.91
CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry (1990) 0.91
Complete amino acid sequences of five dimeric and four monomeric forms of metallothionein from the edible mussel Mytilus edulis. Eur J Biochem (1993) 0.91
The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol (1993) 0.91
Prevalence of Epstein-Barr virus in the cervix. J Clin Pathol (1994) 0.90
Cytochrome P-450 localization in normal human adult and foetal liver by immunocytochemistry using a monoclonal antibody against human cytochrome P-450. Histochem J (1988) 0.90
Sequences of sixteen phosphoserine peptides from ovalbumins of eight species. Eur J Biochem (1981) 0.89
Structural comparison of ovalbumins from nine different species. Eur J Biochem (1970) 0.89
Limited proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s. Eur J Biochem (1990) 0.89
Sublingual capnometry and indexes of tissue perfusion in patients with circulatory failure. Chest (2001) 0.89
Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979-1999. Br J Surg (2005) 0.89
Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer (1999) 0.88
Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem J (1989) 0.88
Monoclonal antibodies against human cytochrome P-450 recognizing different pregnenolone 16 alpha-carbonitrile-inducible rat cytochromes P-450. Biochem J (1987) 0.87
Immunoglobulin concentration in mothers with leprosy and in healthy controls and their babies at the time of birth. Lepr Rev (1980) 0.87
Spot the differences: proteomics in cancer research. Lancet Oncol (2001) 0.87
Expression of cytochrome P450IA in breast cancer. Br J Cancer (1991) 0.87
Antibodies against Mycobacterium leprae antigen 7 from birth to 18 months of age: an indicator of intra-uterine infection in leprosy. Clin Exp Immunol (1980) 0.87
The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line. FEBS Lett (1988) 0.87
Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer (1998) 0.85
Structure and activity of C1r and C1s. Philos Trans R Soc Lond B Biol Sci (1984) 0.85
Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer (2004) 0.85
Variation in drug-metabolizing enzyme activities during the growth of human Hep G2 hepatoma cells. Xenobiotica (1990) 0.84
The plant mitochondrial F1-ATPase. The identity of the delta' (20 kDa) subunit. FEBS Lett (1990) 0.84
The relation of metabolism to macromolecular binding of the carcinogen benzo[a]pyrene, by mouse embryo cells in culture. Int J Cancer (1970) 0.84
IgA and IgM antibodies against Mycobacterium leprae in cord sera and in patients with leprosy: an indicator of intrauterine infection in leprosy. Scand J Immunol (1981) 0.84
Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur J Clin Invest (1989) 0.83
The purification and characterization of subcomponent C1s of the first component of bovine complement. Biochem J (1979) 0.83
A general method for affinity purification of complement component C3b using factor H-sepharose. Biochem J (1982) 0.83
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol (1995) 0.83
Trends in mortality rates for death-certificate-coded diabetes mellitus in an English population 1979-99. Diabet Med (2004) 0.83
Plant mitochondrial F1-ATPase. The presence of oligomycin-sensitivity-conferring protein (OSCP). Biochem J (1989) 0.82
A simple enzyme-linked immunosorbent assay (ELISA) for the neuron-specific gamma isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. J Immunol Methods (1992) 0.82
Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney. J Histochem Cytochem (1995) 0.82
Differences in adult and foetal human cytochrome P-450 forms recognized by monoclonal antibodies with specificity for the P450III family. Biochem J (1989) 0.82
Metabolism and macromolecular binding of dibenz(a,c)anthracene and dibenz(a,h)anthracene by mouse embryo cells in culture. Int J Cancer (1972) 0.82
Trends in mortality for cancers, comparing multiple- and underlying-cause rates, in an English population 1979-1999. Br J Cancer (2004) 0.82
Onset of ribosome degradation during cessation of growth in BHK-21/C13 cells. Biochem J (1978) 0.81
Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol (1987) 0.80